deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT04601285

A Phase I Study of JS108 in Patients With Advanced Solid Tumors

A Phase I, Open-label, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Recombinant Humanized Anti-Trop2 mAb-Tub196 Conjugate in Patients With Advanced Solid Tumors.

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Advanced Solid Tumors
Interventions JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
Updated 7 times since 2020 Last updated: Jul 4, 2023 Started: Oct 28, 2020 Primary completion: Jun 14, 2023 Completion: Jun 14, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor has adjusted study development plan and terminated this clinical study.

Other terminated trials from Shanghai Junshi Bioscience Co., Ltd.

More terminations from Shanghai Junshi Bioscience Co., Ltd.

Other Advanced Solid Tumors trials with similar outcome

Browse all Advanced Solid Tumors trials

Listed as NCT04601285, this PHASE1 trial focuses on Advanced Solid Tumors and remains terminated or withdrawn. Sponsored by Shanghai Junshi Bioscience Co., Ltd., it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshotRecruiting~May 2022 – ~Aug 2023 · 15 months · monthly snapshotRecruiting~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Aug 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Recruiting → Terminated

  4. May 2022 — Aug 2023 [monthly]

    Recruiting PHASE1

  5. May 2021 — May 2022 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

▶ Show 2 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

  2. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Junshi Bioscience Co., Ltd.
Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations